Log in

NASDAQ:GNPX - Genprex Stock Price, Forecast & News

+0.02 (+8.00 %)
(As of 12/16/2019 04:36 AM ET)
Today's Range
Now: $0.27
50-Day Range
MA: $0.38
52-Week Range
Now: $0.27
Volume221,848 shs
Average Volume1.12 million shs
Market Capitalization$4.28 million
P/E RatioN/A
Dividend YieldN/A
Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GNPX



Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share


Net Income$-12,370,000.00


Market Cap$4.28 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive GNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

Genprex (NASDAQ:GNPX) Frequently Asked Questions

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

How were Genprex's earnings last quarter?

Genprex Inc (NASDAQ:GNPX) issued its quarterly earnings data on Monday, April, 1st. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.10. View Genprex's Earnings History.

When is Genprex's next earnings date?

Genprex is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Genprex.

What price target have analysts set for GNPX?

2 brokerages have issued 12-month target prices for Genprex's shares. Their forecasts range from $5.00 to $5.00. On average, they expect Genprex's share price to reach $5.00 in the next year. This suggests a possible upside of 1,752.5% from the stock's current price. View Analyst Price Targets for Genprex.

What is the consensus analysts' recommendation for Genprex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genprex.

Has Genprex been receiving favorable news coverage?

News headlines about GNPX stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genprex earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Genprex.

Are investors shorting Genprex?

Genprex saw a increase in short interest in November. As of November 29th, there was short interest totalling 366,800 shares, an increase of 270.5% from the November 14th total of 99,000 shares. Based on an average trading volume of 409,700 shares, the short-interest ratio is currently 0.9 days. Currently, 3.4% of the shares of the stock are sold short. View Genprex's Current Options Chain.

Who are some of Genprex's key competitors?

What other stocks do shareholders of Genprex own?

Who are Genprex's key executives?

Genprex's management team includes the folowing people:
  • Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)
  • Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)
  • Mr. Ryan M. Confer, Chief Financial Officer (Age 37)
  • Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board

Who are Genprex's major shareholders?

Genprex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sabby Management LLC (3.64%). Company insiders that own Genprex stock include Jack A Roth, John Rodney Varner and Julien L Pham. View Institutional Ownership Trends for Genprex.

Which institutional investors are selling Genprex stock?

GNPX stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Genprex.

How do I buy shares of Genprex?

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $0.27.

How big of a company is Genprex?

Genprex has a market capitalization of $4.28 million. The company earns $-12,370,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. View Additional Information About Genprex.

What is Genprex's official website?

The official website for Genprex is http://www.genprex.com/.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-370-4081 or via email at [email protected]

MarketBeat Community Rating for Genprex (NASDAQ GNPX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Genprex and other stocks. Vote "Outperform" if you believe GNPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel